AngioDynamics (NASDAQ: ANGO) Price Target Raised Amid Strong Financial Performance

• An analyst has increased the price target for AngioDynamics (NASDAQ: ANGO) to $19.00, suggesting a potential upside of 31.12%.
• AngioDynamics consistently exceeded revenue estimates, reporting fourth-quarter revenues of $86.60 million, an 8.00% increase year-over-year.
• The company's Med Tech division saw significant growth of 16.70%, driven by strong sales of its NanoKnife and AlphaVac products.

On July 15, 2026, an analyst from H.C. Wainwright increased the price target for AngioDynamics (NASDAQ: ANGO) to $19.00. This new target suggests a potential upside of about 31.12% from its trading price of $14.49 at the time. This medical technology stock focuses on improving blood flow and expanding cancer treatment options, a key area for healthcare innovation.

This optimistic outlook follows strong financial results. As highlighted by Zacks, AngioDynamics reported fourth-quarter revenues of $86.60 million, an 8.00% increase from the previous year. This performance exceeded analyst expectations. The company has now beaten revenue estimates for four straight quarters, showing a consistent pattern of strong sales performance.

The revenue growth is mainly from AngioDynamics' Med Tech division, which saw sales increase by 16.70%. This was led by significant growth in its NanoKnife and AlphaVac products, which grew by 64.50% and 38.40%, respectively. These innovative products are key to the company's strategy of restoring healthy blood flow and treating patients, showcasing its commitment to advanced healthcare solutions.

For the quarter, AngioDynamics reported an adjusted loss of $0.07 per share. While this is a wider loss than the $0.03 per share from the same period last year, it was better than the expected loss of $0.11 per share. This earnings per share figure is a crucial financial metric that shows how much profit or loss the company makes for each share of its stock.

Looking forward, the company projects sales for fiscal year 2027 to be between $336 million and $341 million. As highlighted by Business Wire, AngioDynamics' recent performance has also pushed its stock to a new 52-week high of $14.80, reflecting positive investor sentiment following the record financial results and strong stock performance.